Hikal Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
Hikal reported Q4 FY26 revenue of INR519 crores with EBITDA margin at 20.3%, while full-year FY26 revenue stood at INR1,713 crores with EBITDA margin at 12.9%. Management attributed the quarterly improvement to recovery in Pharma demand trends and a rebound in Crop Protection volumes following industry inventory correction, while noting an exceptional impairment charge of INR47 crores on a multipurpose manufacturing facility at Panoli. Management also discussed an ongoing US FDA warning letter affecting the Bangalore pharma site, which slowed shipments and production in the year, alongside continued investment in CDMO, HPAPI and Animal Health capabilities.